Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Plans To File Arxxant NDA On Strength Of Single Phase III Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

The company will pursue a diabetic nephropathy indication for the protein kinase C-beta inhibitor following initial submission for diabetic retinopathy.

You may also be interested in...



Lilly’s Arxxant Granted Priority Review For Diabetic Retinopathy

Phase III trials are ongoing for additional indications for the protein kinase C-beta inhibitor ruboxistaurin.

Lilly’s Arxxant Granted Priority Review For Diabetic Retinopathy

Phase III trials are ongoing for additional indications for the protein kinase C-beta inhibitor ruboxistaurin.

Lilly Focuses On Ruboxistaurin Retinopathy NDA After Failed Neuropathy Trials

Two trials of reboxistaurin (proposed trade name Arxxant) in diabetic peripheral neuropathy fail to demonstrate statistically significant differences in sensory symptom scores.

Topics

UsernamePublicRestriction

Register

IV001392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel